Andrew Goldsweig

Dr. Andrew Goldsweig serves as an Associate Professor of Medicine at UMass Chan Medical School's Baystate Regional Campus in Springfield, Massachusetts. With a strong academic foundation including a BS in Chemistry from MIT, an MS in Clinical Translation Research from the University of Nebraska Medical Center, and an MD from New York University, he has established himself as a prominent researcher in interventional cardiology.

Dr. Goldsweig's research interests focus on transcatheter aortic valve replacement (TAVR), percutaneous coronary intervention (PCI), structural heart disease, and cardiovascular outcomes research. His work frequently employs meta-analyses and systematic reviews to evaluate the efficacy and safety of various cardiac interventions. Notably, his publication record shows significant growth, with 40 publications in 2024 alone and 14 already in 2025, demonstrating his active contribution to advancing knowledge in interventional cardiology.

His recent publications reveal several key trends: an emphasis on comparative effectiveness research between different cardiac interventions, investigation of imaging modalities for guiding procedures, examination of health disparities in cardiovascular care, and analysis of optimal management strategies for complex cardiac conditions. Dr. Goldsweig frequently collaborates with major research groups including the National Cardiogenic Shock Initiative and contributes to high-impact journals such as Circulation, JACC, and European Heart Journal.

As an educator and researcher, Dr. Goldsweig has contributed to numerous professional guidelines and consensus statements, including those from the Society for Cardiovascular Angiography and Interventions (SCAI). His work bridges clinical practice with evidence-based medicine, focusing on improving patient outcomes through rigorous scientific investigation of cardiovascular interventions.